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In sub-Saharan Africa, diagnosis and management of extrapulmonary tuberculosis (EPTB)
in people living with HIV (PLHIV) remains a major challenge. This study aimed to character-
ize the epidemiology and risk factors for poor outcome of extrapulmonary tuberculosis in
people living with HIV (PLHIV) in a rural setting in Tanzania.
Methods
We included PLHIV >18 years of age enrolled into the Kilombero and Ulanga antiretroviral
cohort (KIULARCO) from 2013 to 2017. We assessed the diagnosis of tuberculosis by inte-
grating prospectively collected clinical and microbiological data. We calculated prevalence-
and incidence rates and used Cox regression analysis to evaluate the association of risk
factors in extrapulmonary tuberculosis (EPTB) with a combined endpoint of lost to follow-up
(LTFU) and death.
Results
We included 3,129 subjects (64.5% female) with a median age of 38 years (interquartile
range [IQR] 31–46) and a median CD4+ cell count of 229/μl (IQR 94–421) at baseline. Dur-
ing the median follow-up of 1.25 years (IQR 0.46–2.85), 574 (18.4%) subjects were diag-
nosed with tuberculosis, whereof 175 (30.5%) had an extrapulmonary manifestation.
Microbiological evidence by Acid-Fast-Bacillus stain (AFB-stain) or Xpert® MTB/RIF was
present in 178/483 (36.9%) patients with pulmonary and in 28/175 (16.0%) of patients with
extrapulmonary manifestations, respectively. Incidence density rates for pulmonary Tuber-
culosis (PTB and EPTB were 17.9/1000person-years (py) (95% CI 14.2–22.6) and 5.8/1000
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py (95% CI 4.0–8.5), respectively. The combined endpoint of death and LTFU was observed
in 1058 (33.8%) patients, most frequently in the subgroup of EPTB (47.2%). Patients with
EPTB had a higher rate of the composite outcome of death/LTFU after TB diagnosis than
with PTB [HR 1.63, (1.14–2.31); p = 0.006]. The adjusted hazard ratios [HR (95% CI)] for
death/LTFU in EPTB patients were significantly increased for patients aged >45 years [HR
1.95, (1.15–3.3); p = 0.013], whereas ART use was protective [HR 0.15, (0.08–0.27); p
<0.001].
Conclusions
Extrapulmonary tuberculosis was a frequent manifestation in this cohort of PLHIV. The diag-
nosis of EPTB in the absence of histopathology and mycobacterial culture remains challeng-
ing even with availability of Xpert® MTB/RIF. Patients with EPTB had increased rates of
mortality and LTFU despite early recognition of the disease after enrollment.
Introduction
Tuberculosis (TB) remains a leading cause of death, especially in patients co-infected with
HIV. Of the 10 million patients diagnosed with TB globally in 2017, 9% were co-infected with
HIV. Of these, 72% live in Africa and contribute 84% of the 300’000 deaths [1]. Tanzania is
one of the thirty high-endemic countries with an estimated TB incidence rate of 269/100’000
in the general population, an HIV-TB coinfection rate of 31% and a mortality rate in HIV-co-
infected patients of 39/100’000 [1].
While TB is primarily a pulmonary disease, extrapulmonary manifestations account for
14% of incident TB cases worldwide [1]. In countries with a high HIV/TB co-infection rate
such as Tanzania, 20% of incident TB manifest as extrapulmonary TB (EPTB) [1]. TB can
affect any organ—however, lymph nodes and pleura are the most frequent localizations [2, 3].
In African settings TB lymphadenitis has accounted for 61%–78% and TB pleurisy for 10.6%
of EPTB cases [4–6].
Diagnosis of EPTB remains challenging in resource-limited settings, as clinical manifesta-
tions are diverse, microbiological testing depends on invasive procedures and the gold stan-
dard of mycobacterial culture or supporting histopathology is mostly unavailable. The low
bacillary load in tissues leads to poor sensitivity of microscopy for acid-fast bacilli (AFB) [7].
In a recent metanalysis on a wide range of different samples including cerebrospinal fluid,
lymph nodes and a variety of tissues of patients with suspected EPTB, Xpert1MTB/RIF
showed a high specificity of� 98% in cerebrospinal fluid, pleural fluid, urine, and peritoneal
fluid compared to culture, whereas the sensitivity ranged from 31% in pleural tissue to> 80%
in urine and bone or joint fluid and tissue and 97% in bone or joint fluid compared to culture
[8].
This low sensitivity of microbiological tests and the lack of diagnostic tools for important
differential diagnoses of EPTB, e.g. malignancy or heart failure in case of pleural effusions [9],
result in diagnostic uncertainty. As a consequence, many patients with compatible symptoms
receive anti-tuberculous treatment without confirmatory testing [10], resulting in overtreat-
ment of tuberculosis, and underdiagnosis of alternative conditions [11, 12].
Data on outcome and predictors of survival are scarce and most knowledge comes from ret-
rospective studies. Poor outcomes have been reported in patients with central nervous mani-
festations [13], lymphopenia [14], older age and late presentation [15].
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Our study aimed to characterize the epidemiology of EPTB in people living with HIV
(PLHIV) in a rural setting in Tanzania, and to evaluate risk factors of poor outcomes such as
LTFU or death and predictors for this outcome.
Methods
Study site and patient population
For this prospective study, we included all patients aged�18 years enrolled into the Kilombero
and Ulanga Antiretroviral Cohort (KIULARCO) between January 1st, 2013 until December
31st, 2017 who completed a baseline evaluation and at least one clinical follow-up. Exclusion
criteria were lack of informed consent, no follow-up visits or age<18years.
The KIULARCO is an ongoing cohort of HIV-infected patients in care at the Chronic Dis-
eases Clinic Ifakara (CDCI) located at the St. Francis Referral Hospital in the southwest of Tan-
zania. Since its starts 2005, KIULARCO has enrolled more than 10,000 consenting patients
with approximately 4,000 patients currently under active follow-up. The CDCI provides ser-
vices for HIV according to guidelines issued by the national AIDS control program (NACP).
While initially treatment guidelines recommended start of cART for patients with an HIV
infection WHO stage III/IV or CD4 cell count below 350cells/ul [16], the CD4 threshold was
adapted to 500cells/ul in 2013 [17] and removed to allow treatment for all in 2015 [18].
Within routine care, stable patients are assessed by a clinician 4 times per year. During
clinical visits, information on demographics, clinical parameters, co-morbidities, prescription
of cART and co-medications, adherence and laboratory monitoring are entered into a custom-
ized electronic clinical record system designed for subsequent scientific analysis (OpenMRS,
http://openmrs.org) [19, 20]. In 2012, the clinic integrated TB services and implemented sys-
tematic screening for TB with the World Health Organization (WHO) symptom screening
tool and Xpert1MTB/RIF for patients with suspected TB (Cepheid, USA) [21–24]. In patients
suspected of PTB, sputum smear and, in patients with EPTB, urine or a sample from a sterile
site is examined by bacilloscopy and Xpert1MTB/RIF analysis. In addition, from July 2016 to
June 2017, a prospective observational study on the value of sonography to rule out tuberculo-
sis was performed at St. Francis Referral Hospital according to the Focused Assessment with
Sonography for HIV and Tuberculosis protocol (FASH) [25]. The study included HIV-positive
and -negative patients with symptoms of TB and comprised performance of sonography to
detect pleural or cardiac effusion, tuberculoma of liver and spleen, ascites, abdominal lymph-
adenopathy and ileum wall thickening. Xpert1MTB/RIF testing from sputum, urine samples
and sterile fluids (thoracentesis, pericardiocentesis, ascites tap) improving standards for diag-
nosis of TB.
Definitions
To define PTB and EPTB, the International Classification of disease (ICD-10) [26] code and
results from microbiological tests were used (S1 Table). Due to the unavailability of a local
pathology service, no histopathological features were included in the disease definitions.
Microbiologically confirmed PTB was diagnosed, if a sputum sample was positive or an
ICD-10 code for PTB (A15.x and A16.x except A15.6 and A16.5) was documented, and TB
treatment was initiated 1 week before until 3 months after the working diagnosis of suspected
TB. Microbiologically confirmed EPTB was diagnosed, if acid-fast bacilli on microscopy or
Xpert1MTB/RIF were positive from an extrapulmonary site. Additionally, if an ICD-code for
TB pleurisy (A15.6) was documented and anti-TB treatment was started 1 week before until 3
months after the working diagnosis, the infection was considered as confirmed. Microbiologi-
cally confirmed combined PTB and EPTB was defined as either a) presence of acid-fast bacilli/
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positive Xpert MTB/RIF from sputum and A15.6, A17, A18 or A19 or b) presence of acid-fast
bacilli/positive Xpert MTB/RIF from a sterile site and cough or infiltrate on a chest x-ray with-
out an alternative explanation.
Clinical PTB was defined as ICD-10 code A16 (excluding A16.5) without microbiological
confirmation and start of TB treatment 1 week before until 3 months after working diagnosis
of suspected TB. Clinical EPTB was defined as ICD-10 code A16.5, A17, A18, A19 without
microbiological confirmation and without cough or infiltrate on chest x-ray, and start of TB
treatment 1 week before until 3 months after working diagnosis of suspected TB.
Combined clinical PTB and EPTB was defined as A16.5, A17, A18, A19 and presence of
cough or infiltrate on chest x-ray without microbiological confirmation, and initiation of an
anti-tuberculous treatment starting 1 week before until 3 months after an established working
diagnosis.
No presence of tuberculosis was defined as absence of positive microbiological results,
ICD-10 code for tuberculosis and no initiation of anti-tuberculosis therapy.
Cases of TB diagnosed during the first 90 days of observation after enrollment were judged
as prevalent at enrolment to allow for delays in diagnoses in order to prevent over classification
of incident cases. Group descriptions using the term “extrapulmonary manifestation” include
patients in the EPTB as well as the EPTB/PTB group.
Anemia was defined as ICD-10 codes D50-D64.9 or by a hemoglobin level below 12g/l or
11g/l for men and women, respectively. Arterial hypertension was defined as ICD-10 codes
I10—I15 or measured blood pressure of>140/90mmHg upon two consecutive measurements
or active antihypertensive treatment. Undernutrition was defined as ICD-10 codes E44-E46 or
a body mass index (BMI) <18.5kg/m2, obesity as E66.0-E66.9 or a BMI >30.0kg/m2. Acute
kidney failure was diagnosed by ICD-10 codes N17.0–17.9, chronic kidney failure by N18.0–
18.9 or an uninterrupted estimated glomerular filtration rate (according to the CKD-EPI for-
mula)<60ml/min/1.73m2 for > 3 months.
Patients were considered being lost to follow-up (LTFU) if they did not present to the clinic
within 60 days after their last scheduled appointment. We decided to use a composite clinical
outcome of death and LTFU due to a significant rate of LTFU in our cohort and an assumed
high mortality in those patients. [27].
Data management and analysis
All included patients were assigned to the 4 following groups: PTB, EPTB, combined PTB
and EPTB and no TB. Continuous variables were summarized using median and interquartile
range and categorical variables with counts and frequencies. Comparisons of continuous
and categorical variables were done using the Mann–Whitney U test and the chi-square test,
respectively. Prevalence and incidence density rates (i.e. count of incident cases per 1000py of
subjects at risk) were calculated including confirmed and clinically diagnosed cases of tubercu-
losis. Kaplan–Meier estimates were used to plot cumulative survival probabilities. An univari-
able Cox proportional hazard model was used to model time to the composite outcome of lost
to follow-up (LTFU) and death after TB diagnosis in the three subgroups with TB. Univariable
and multivariable Cox proportional hazards models were fitted for patients with EPTB (period
starting from the date of first diagnosis of EPTB) to explore associations of a priori defined
variables (sex, age, CD4+ cell count at baseline, WHO stage at baseline, cART and CNS mani-
festations of TB) with the composite outcome of LTFU and death. The age variable was dichot-
omized at the upper quartile of the distribution of the cohort. The proportional hazard
assumption was checked using Schoenfeld residuals. Missing data were excluded (complete
case analysis). All statistical analyses were performed using Stata 12.1 (StataCorp, USA).
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Ethical considerations
All participants involved in this study gave written informed consent for the collection, storage
and use of clinical data for research purposes within KIULARCO. The study protocol of KIU-
LARCO has been approved by the Ifakara Health Institute Institutional Review Board, the
National Institute of Medical Research in Tanzania, the Tanzanian Commission of Science
and Technology as well as the Ethics committee of Northwest and Central Switzerland.
Results
Study population
In total, 3,620 patients were enrolled into KIULARCO between January 1st 2013 and Decem-
ber 31st 2017. Of these, we excluded 363 patients <18 years of age and 128 patients without
any follow-up visits, resulting in 3,129 patients included in the final analysis (Fig 1). No charac-
terization of the 128 patients excluded was done due to high rates of missing values. The
median follow-up time was 1.25 years (IQR 0.46–2.85, range 3 days to 5 years) resulting in a
total of 5370 person-years of follow-up.
Baseline characteristics of patients at the time of enrolment into KIULARCO according to
TB group are shown in Table 1. The median age ranged from 36.5 years (IQR 31.3, 42.6) in the
EPTB group to 39.9 years (IQR 34.0, 46.8) in the PTB group. The majority of patients (64.7%)
were females, only the subgroup of patients with combined PTB and EPTB comprised more
males (54.8%). The HIV infection at enrolment was more advanced in patients with a consecu-
tive diagnosis of TB at any location: WHO stage 3/4 was attributed to 34.7% in the no TB
Fig 1. Flowchart of patients included in the study. Patients screened and included in the study. After inclusion,
patients were allocated to 4 groups: patients with no tuberculosis (no TB), patients with pulmonary Tuberculosis
(PTB), patients with extrapulmonary tuberculosis (EPTB) and patients with pulmonary and extrapulmonary
tuberculosis. LTFU, lost to follow-up.
https://doi.org/10.1371/journal.pone.0229875.g001
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Table 1. Baseline characteristics.
EPTB PTB PTB and EPTB no TB p-value
N (total = 3129) 91 399 84 2555
Microbiologically confirmed TB 8 (8.8%) 144 (36.1%) 34 (40.4%)£, 20 (23.8%)$ -
Positive Xpert1 MTB/RIF 7 (7.7%) 84 (21.0%) 16 (19%)£ / 12 (14.3%)$ -
Year of registration <0.001
2013 15 (16.5%) 57 (14.3%) 8 (9.5%) 332 (13.0%)
2014 16 (17.6%) 112 (28.1%) 17 (20.2%) 476 (18.6%)
2015 26 (28.6%) 133 (33.3%) 32 (38.1%) 630 (24.7%)
2016 17 (18.7%) 64 (16.0%) 9 (10.7%) 548 (21.4%)
2017 17 (18.7%) 33 (8.3%) 18 (21.4%) 569 (22.3%)
Age, years, median (IQR) 36.5 (31.3, 42.6) 39.9 (34.0, 46.8) 39.9 (33.6, 45.5) 38.0 (31.2, 46.2) 0.007
Sex, female 55 (60.4%) 214 (53.6%) 38 (45.2%) 1716 (67.2%) <0.001
Marital status 0.001
Married/living in relationship 54 (59.3%) 205 (51.4%) 54 (64.3%) 1581 (61.9%)
Living alone 37 (40.7%) 194 (48.6%) 30 (35.7%) 974 (38.1%)
Smoking, current 8 (8.8%) 37 (9.3%) 7 (8.3%) 102 (4.0%) <0.001
Missing information 2 (2.2%) 14 (3.5%) 2 (2.4%) 233 (9.1%)
Alcohol consumption, current 14 (15.4%) 67 (16.8%) 9 (10.7%) 297 (11.6%) 0.12
Missing information 2 (2.2%) 14 (3.5%) 2 (2.4%) 233 (9.1%)
HIV WHO stage <0.001
1 14 (15.4%) 45 (11.3%) 9 (10.7%) 1086 (42.5%)
2 7 (7.7%) 29 (7.3%) 2 (2.4%) 385 (15.1%)
3 27 (29.7%) 238 (59.6%) 37 (44.0%) 588 (23.0%)
4 42 (46.2%) 80 (20.1%) 35 (41.7%) 299 (11.7%)
Missing information 1 (1.1%) 7 (1.8%) 1 (1.2%) 197 (7.7%)
CD4+ cell count (/μl) <0.001
<100 30 (33.0%) 160 (40.1%) 29 (34.5%) 459 (18.0%)
100–199 21 (23.1%) 67 (16.8%) 20 (23.8%) 387 (15.1%)
200–499 25 (27.5%) 83 (20.8%) 21 (25.0%) 837 (32.8%)
> = 500 7 (7.7%) 33 (8.3%) 2 (2.4%) 439 (17.2%)
Missing information 8 (8.8%) 56 (14.0%) 12 (14.3%) 433 (16.9%)
CD4+ count (/μl), median (IQR) 159 (60, 303) 113 (49, 280) 128 (54, 220) 262 (117, 450) <0.001
Comorbidities
Anemia 72 (80.0%) 292 (73.2%) 72 (85.7%) 1189 (46.6%) <0.001
Thrombocytopenia 15 (16.7%) 58 (14.5%) 13 (15.5%) 300 (11.8%) 0.18
Undernutrition 21 (23.3%) 151 (37.8%) 24 (28.6%) 359 (14.1%) <0.001
Obesity 1 (1.1%) 11 (2.8%) 2 (2.4%) 136 (5.3%) 0.030
Arterial Hypertension 10 (11.1%) 40 (10.0%) 10 (11.9%) 377 (14.8%) 0.059
Cryptococcosis 3 (3.3%) 8 (2.0%) 1 (1.2%) 56 (2.2%) 0.80
Viral hepatitis 4 (4.4%) 26 (6.5%) 6 (7.1%) 140 (5.5%) 0.73
Acute kidney failure 5 (5.6%) 9 (2.3%) 6 (7.1%) 33 (1.3%) <0.001
Chronic kidney failure 0 (0.0%) 2 (0.5%) 2 (2.4%) 21 (0.8%) 0.28
Malaria 8 (8.9%) 55 (13.8%) 10 (11.9%) 206 (8.1%) 0.002
Lower respiratory tract infection 4 (4.4%) 60 (15.0%) 7 (8.3%) 195 (7.6%) <0.001
EPTB, extrapulmonary tuberculosis; IQR, interquartile range; PTB, pulmonary tuberculosis; TB, tuberculosis; WHO, world health organisation
£ positive sputum sample;
$ positive extrapulmonary sample
https://doi.org/10.1371/journal.pone.0229875.t001
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group versus 79.7%, 75.9% and 85.7% of the PTB, EPTB and PTB/EPTB group, respectively.
The highest median CD4+ cell count was observed in the no TB group with 262 cells/μl,
whereas in all other groups the median count was<200 cells/μl (113, 159 and 128 cells/μl in
the PTB, EPTB and PTB/EPTB group, respectively). Patients with EPTB were more frequently
married and less frequently smokers.
Regarding comorbidities within the first three months after enrolment, anemia was highly
prevalent in all groups, but more so in patients with TB with the highest prevalence in the
PTB/EPTB group with up to 85.7%. Undernutrition was also more prevalent in TB groups (no
TB 14.1%, PTB 37.8%, EPTB 23.3%, PTB/EPTB 28.6%).
Prevalence and incidence of EPTB, PTB and combined PTB/EPTB
Overall, 574 (18.4%) patients were diagnosed with confirmed or clinical TB at any localization
(Fig 1). An extrapulmonary manifestation was observed in 175 (5.6%) patients, whereof 84
(48%) had concurrent pulmonary TB (PTB and EPTB group) and 91 (52%) no signs of pulmo-
nary TB (EPTB group). Exclusive pulmonary manifestations were documented in 399 (12.8%)
patients (PTB group).
The diagnosis of EPTB was made a median of 3.5 (IQR 1–21.5, range 0–1181) days and
PTB at 2 (IQR 1–17, range 0–1296) days after enrolment. Most cases of TB were diagnosed
during the first 90 days of observation and thus classified as prevalent at enrolment: this was
the case in 334 (83.7%) in PTB, 78 (85.7%) in EPTB and 71 (84.5%) in PTB/EPTB. Tuberculo-
sis diagnoses occurring 3 months or later after enrolment (incident cases) were diagnosed at
an incidence density rate of 17.9/1000py (95% CI 14.2–22.6) for PTB and 5.8/1000py (95% CI
4.0–8.5) for EPTB corresponding to 5 cases of PTB, and 13 cases of EPTB and EPTB/PTB
each.
Analyzing the time point of diagnosis of TB in relation to start of cART, in the majority of
patients (406/508; 71.8%) TB was diagnosed before start of cART (Fig 2). No further informa-
tion from the clinical notes concerning possible TB-associated immune reconstitution inflam-
matory syndrome (TB-IRIS) was available. In the subset of patients with initiation of cART
ahead of a diagnosis of an incident case of TB, the median time from initiation of cART to
the diagnosis of PTB and EPTB was 285 days (IQR 128–659) and 305 days (IQR 114–752,
p = 0.78), respectively, possibly representing unmasking IRIS cases.
Clinical presentation and microbiological testing
Affected organs in the 175 patients (multiple per patient possible) diagnosed with EPTB or
PTB/EPTB were pleural space in 42 (24.0%), lymph node in 41 (23.4%), pericardium in 32
(18.3%), central nervous system in 21 (12%), urogenital tract in 18 (10.3%), peritoneum in 17
(9.7%), miliary in 13 (7.4%), bone in 2 (1.1%) and other in 21 (12.0%) of patients.
In total, 178/483 (36.9%) of patients with a pulmonary manifestation (i.e. the PTB and the
combined PTB/EPTB group) and 28/175 (16.0%) of patients with an extrapulmonary manifes-
tation were confirmed microbiologically (Table 1).
In total, we tested 1,241 samples (of 807 patients) with Xpert1MTB/RIF, whereof 500
(40.2%) were of extrapulmonary origin. Overall, 157/1241 (12.7%) samples analyzed were pos-
itive. Sputum samples were positive in 132/741 (17.8%) samples, extrapulmonary samples in
25/500 (5.0%) samples (Table 2). Over the study period, the number of performed Xpert1
MTB/RIF tests per year increased for all materials with maximum usage in 2017 (S1 Dataset).
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Treatment and outcome
Combined antiretroviral therapy (cART) according to national guidelines was initiated in
2,786 (89.0%) of included patients after a median of 6 days (IQR 1–19 days, 90th percentile 102
days) from enrolment in the cohort. Out of the 574 patients with any diagnosis of TB, 508
(88.5%) started cART after a median of 23 (IQR 10–56) days. In the subset of patients with
EPTB (including PTB/EPTB), 148 (82%) started cART after a median of 20 (IQR 7–40) days
after enrolment. The most frequent combinations of antiretrovirals initiated were tenofovir
disoproxil/lamivudine/efavirenz in 1,911 (68.5%) and tenofovir disoproxil/emtricitabine/efa-
virenz in 423 (15.2%) of patients started on cART.
Fig 2. Interval between start of antiretroviral treatment and diagnosis of tuberculosis. (A) extrapulmonary
tuberculosis (EPTB), (B) pulmonary tuberculosis (PTB). Time point “0” denotes the initiation of cART, negative values
indicate that the diagnosis of TB was preceding the initiation of cART.
https://doi.org/10.1371/journal.pone.0229875.g002
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Table 3 and Fig 3 show the numbers of patients who died or were lost to follow-up. Overall,
154 (4.9%) patients died (14.3% of patients with EPTB, 8.5% of patients with PTB and 3.7% of
patients without TB). The combined endpoint of death/LTFU was most frequent in patients
with EPTB (47.2% for EPTB alone, 46.4% for PTB/EPTB). The crude hazard ratios [HR (95%
CI)] for death/LTFU after a diagnosis of TB were increased in the EPTB [HR 1.63, (1.14–2.31);
p = 0.006] and the combined EPTB and PTB subgroup [HR 1.65, (1.15–2.46); p = 0.006] in
comparison with the PTB subgroup (Fig 3).
Cox proportional hazard models were fitted using the data of all 175 with an EPTB (EPTB
and PTB/EPTB group) to analyze factors associated with the composite outcome of death and
LTFU (Table 4). In both the univariable and multivariable model, patients with EPTB, who
have ever received cART had a significantly decreased risk of death/LTFU compared to
patients who were not yet on cART (HR 0.15, 95% CI 0.08–0.27). The multivariable hazard
ratios for death/LTFU were significantly increased for patients aged>45 years (HR 1.95, 95%
CI 1.15–3.3).
Discussion
In this rural sub-Saharan African cohort of PLHIV we found an EPTB prevalence of 5.6% with
a high mortality of 14.3% (25/175) and a combined death/LTFU rate of 46.8%. Diagnosis
remains a major challenge as only 36.9% of all pulmonary TB manifestations and 16% of extra-
pulmonary manifestations were confirmed by microbiology. Patients with EPTB not receiving
cART and with an age>45 years had a higher risk for a poor outcome.
The overall TB prevalence of 18.4% in our study is comparable to the UNAIDS Report 2018
showing a TB prevalence of 16% in PLHIV [28]. However, the 30% of EPTB within TB cases is
considerably higher than rates documented worldwide and in Tanzania (14%, 22%, respec-
tively) [1]. Studies from other rural sub-Saharan African settings, e.g. Ethiopia, also found a
high EPTB prevalence in PLHIV (36.8%) [29]. Reasons might be the high number of patients
presenting with advanced HIV (65%) and co-factors such as undernutrition [19, 30], which
Table 2. Count and proportion of positive GeneXpert MTB/RIF by patient group (multiple tests per patients possible).
EPTB PTB PTB and EPTB No TB Total
Sputum 0/28 106/275 (38.5%) 26/42 (61.9%) 0/396 132/741 (17.8%)
CSF 2/10 (20%) 0/12 0/9 0/72 2/103 (1.9%)
Pleural fluid 0/6 0/9 5/18 (27.7%) 0/0 5/33 (15.2%)
Ascitic fluid 1/4 (25%) 0/0 0/3 0/11 1/18 (5.6%)
Urine 4/24 (16%) 0/85 13/46 (28.3%) 0/188 17/343 (5%)
Lymph node 0/0 0/0 0/1 0/2 0/3
multiple tests per patient possible
CSF, cerebrospinal fluid; EPTB, extrapulmonary tuberculosis; PTB, pulmonary tuberculosis; TB, tuberculosis
https://doi.org/10.1371/journal.pone.0229875.t002
Table 3. Composite outcome of death/LTFU.
EPTB (n = 91) PTB (n = 399) EPTB and PTB (n = 84) No TB (n = 2555) p-value
Dead/LTFU 43 (47.2%) 137 (34.3%) 39 (46.4%) 839 (32.8%) 0.003
Dead 13 (14.3%) 34 (8.5%) 12 (14.3%) 95 (3.7%) <0.001
EPTB, extrapulmonary tuberculosis; LTFU, lost to follow-up; PTB, pulmonary tuberculosis; TB, tuberculosis
p-values indicated are derived by multiple group comparison using chi-square tests.
https://doi.org/10.1371/journal.pone.0229875.t003
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has been demonstrated to be 30% in the same cohort [31] and is more prevalent in rural than
in urban settings [32]. Over the study duration, the proportion of patients with a diagnosis of
EPTB in all patients with TB increased from 28.8% in 2013 to 51% in 2017 patients. This might
be likely due to reporting bias, as we concurrently did a prospective study on the impact of
sonography for EPTB diagnosis, leading to a more sensitive evaluation of patients with TB
Fig 3. Kaplan-Meier curves for composite outcome of lost to follow-up/dead in patients with tuberculosis.
https://doi.org/10.1371/journal.pone.0229875.g003
Table 4. Cox proportional hazard model for composite outcome of LTFU/death in EPTB patients (with or without pulmonary manifestation).
Univariable Multivariable
HR (95% CI) p HR (95% CI) p
Female sex a 0.86 (0.52, 1.41) 0.541 0.86 (0.52, 1.41) 0.541
CD4+ cell count at baseline [cells/ul)
<200 Reference Reference
�200 0.87 (0.53, 1.42) 0.59 0.94 (0.56, 1.58) 0.829
WHO stage at baseline
I & II Reference Reference
III & IV 1.10 (0.62, 1.97) 0.743 0.88 (0.46, 1.67) 0.693
Tuberculous meningitis b 0.91 (0.44, 1.89) 0.805 0.71 (0.33, 1.50) 0.363
ART intake c 0.19 (0.11, 0.32) <0.001 0.15 (0.08, 0.27) <0.001
Age > 45 years d 1.35 (0.84, 2.16) 0.214 1.95 (1.15, 3.30) 0.013
ART, antiretroviral therapy; CI, confidence intervall; HR, hazard ratio; LTFU, lost to follow-up; WHO world health organization
Reference groups:
a male sex,
b no tuberculous meningitis,
c no ART intake,
d age� 45 years
https://doi.org/10.1371/journal.pone.0229875.t004
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[25]. In other settings, implementation of cART has led to a decrease in EPTB rates in PLHIV
[33].
The mortality of 14.3% of EPTB patients is lower than a recent study in urban setting in
Ghana with a mortality of 28.7% [34]. However, the rate of 14.3% we found is comparable to a
multicohort study comparing clinical outcomes of EPTB in 22 ART programs with a mortality
of 11.4% in PLHIV with EPTB [35]. Comparison between different studies remains a challenge,
as diagnosis of EPTB is not very standardized and mostly done on clinical parameters only [25].
In our study, the rate of positive Xpert1MTB/RIF was low with 12.7% (157/1,241 samples
analyzed). While the majority of positive samples (86.3%) originated from sputum, the rate of
positive samples from extrapulmonary sites was very low with 5% (25/500). Poor sensitivity of
Xpert1MTB/RIF has been demonstrated in PLHIV with HIV previously [5] and is partly due
to challenges in proper sampling [36] and the paucibacillary nature of disease in PLHIV and in
extrapulmonary sites [37, 38]. In one study overall sensitivity and specificity of Xpert1MTB/
RIF compared to culture was 81.3% and 99.8%, respectively in patients with EPTB. However,
when compared to a combination of culture and clinical diagnosis, the sensitivity of Xpert1
MTB/RIF in cavitary fluids was under 50% [39]. The inclusion of the clinical diagnosis into a
combined gold standard was based on post-mortem studies in PLHIV in resource-limited set-
tings, which have shown a prevalence of TB in sub-Saharan Africa up to 43.2% [40]. A recent
meta-analysis found a sensitivity of Xpert1MTB/RIF in pleural fluid of 50.9% and documents
the important role of Xpert1MTB/RIF as confirmatory test in extrapulmonary samples, while
exclusion remains a challenge [8].
While the majority of TB cases (71.8%) were diagnosed before the start of cART, a minority
(9.1%) were diagnosed in first 30 days after, possibly presenting an unmasking IRIS. This
hyper-responsiveness due to an increase in T-cells [41] has been reported to occur in 36–54%
of TB/HIV co-infected patients [42, 43] and usually occurs within the first month after start of
the antiretroviral therapy [44]. Patients presenting late after cART start with incident TB were
few–unfortunately we could not analyze details on cART adherence or virological suppression
as routine viral load was not implemented during the study period.
In a meta-analysis of PLHIV in sub-Saharan Africa around 40% of patients were LTFU five
years after initiation of cART with death rates approaching 15% [45]. In our cohort this num-
ber was even higher in those with EPTB diagnosis. A recent meta-analysis including data of
7,377 patients who started cART and were subsequently LTFU showed a rate of 21.8% of sub-
jects to be deceased while 14.8% of patients LTFU have been transferred to another clinic [46].
Factors associated with poor outcome in patients with EPTB in our study were age of>45
years and not being on cART. Both confirm previous studies, where age has been shown as a
risk factor for disseminated TB and death [47, 48], while patients with EPTB co-infected with
HIV without cART showed poorer outcomes than with cART [4].
The adjusted model did not show an association between indicators of HIV associated
immunosuppression (WHO stage and CD4+ cell count) at baseline and the combined end-
point. This observation might be due to the inclusion of only patients developing EPTB into
the model. By analyzing a selected group with a high probability of the endpoint as well as a
presumed high level of functional immunodeficiency, WHO stage and CD4+ cell count might
not further discriminate risk.
A major strength of this study is the prospective assessment of TB by means of ICD-10
codes in a long-term cohort of PLHIV ensuring standardized reporting. Furthermore, this
study depicts a sub-Saharan African rural setting representative of settings with limited diag-
nostic resources available to clinicians and a high proportion of diagnoses relying on clinical
presentation only. Those conditions are neglected as many studies have been done in urban
settings.
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The clinical diagnosis of EPTB determined by the physician, however remains a major limi-
tation, as it is a poorly defined entity which might have been assessed differently by physicians.
Patients with important differential diagnoses such as cancer, heart failure, lung abscess or
other diseases might have been missed. As in other studies from African settings [4, 5, 49, 50]
the most frequent sites of EPTB were pleurisy and lymphadenopathy. As the lymphadenopathy
was a clinical diagnosis without histological confirmation, the assumption of TB as underlying
disease might have been overestimated.
Besides improving microbiological detection of TB, e.g. by Xpert MTB/RIF Ultra [51], lat-
eral flow urine lipoarabinomannan assay (LF-LAM) [52] or adenosine deaminase [53, 54], the
clinical evaluation might benefit from integration of an additional standardized testing, such
as e.g. Focused Assessment with Sonography for HIV and Tuberculosis (FASH) [25, 55].
Another limitation is the rather low observation period of patients after start on cART
(median 1.25 years), mainly due to the high number of patients LTFU, which precluded an
exact estimation of the true mortality rate.
In conclusion, EPTB remains a relevant comorbidity with a high mortality and LTFU in a
rural sub-Sahara African setting. Establishing a microbiological diagnosis of EPTB in the
absence of culture and histopathology remains a major challenge in settings, where invasive
diagnostic procedures are not routinely performed. Despite the increasing access to Xpert1
MTB/RIF MTB/RIF in sub-Saharan Africa it remains unclear to what extent this translates in
clinical benefit [56]. The lack of ART as a factor for poor prognosis points at the importance of
early ART start. Further research needs to be conducted to better define clinical predictors and
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